Notre mission : trouver des solutions pour les troubles de l’audition Nous développons des traitements qui pourraient révolutionner la prise en charge des patients atteints de troubles de l’oreille interne
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
Mentions in press and media 5
| Date | Title | Description |
| 07.08.2025 | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) Thu, Aug 07, 2025 07:00 CET Report this content Lund, Sweden August 7, 2025, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in... |
| 09.04.2021 | Sensorion : Announces That a General Meeting of Shareholders Will Be Held Behind Closed Doors on May 18, 2021 Alongside the Publication of Its 2020 Annual Financial Report | Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces ... |
| 21.10.2020 | SENSORION Sensorion : reports 2020 first half results. Financial position strengthened with 31m (US$36.5m) capital raise in September 2020. Read | Press release Sensorion reports 2020 first half results Financial position strengthened with €31m (US$36.5m) capital raise in September 2020 Gene therapy agreement expands pipeline and preclinical data SENS-401Phase II trial progressing wit... |
| 07.07.2020 | SENSORION Sensorion : appoints Dr Edwin Moses, former Ablynx CEO, as Chairman of the Board. Read | Sensorion appoints Dr Edwin Moses, former Ablynx CEO, as Chairman of the Board • Dr Moses is internationally recognized as a leading CEO and Chairman of life science companies • Dr Moses led the rapid growth of Ablynx from a platform techno... |
| 21.01.2015 | Sensorion Completes up to €4M Funding Round | Sensorion S.A., a Montpellier, France-based biotech startup specializing in the treatment of inner ear diseases, completed an up to €4m new funding round. Existing shareholders Innobio and Inserm Transfert Initiative made the investment, wh... |